A GLP-1 tsunami is headed for the vice industry. Good.
A new wave of cheap weight-loss drugs heralds an existential crisis for the sin economy
THERE is a new breed on the rise among us – they look just like your childhood friends and long-time colleagues, but they are no longer the people you used to know.
They are turning up to brunch in athleisure wear, picking at their food and refusing dessert.
Even as their waistlines shrink, the tribe of obesity or GLP-1 drug users is rapidly expanding. Since 2020, prescriptions for drugs such as Wegovy, Ozempic and Mounjaro have more than tripled in the US alone.
TRENDING NOW
DBS, OCBC, UOB rout lops billions off STI as inflation, rate concerns spook investors
Grab CEO’s wife Chloe Tong on life with Anthony Tan and finding her purpose
OCBC sheds S$8 billion in value as shares close nearly 6% down; analysts cautious on banks
Deal between tycoon friends sparks scrutiny of Philippine power sector
